was superior to salmeterol (long-acting inhaled β 2 agonist medication) in preventing COPD exacerbations. In this randomized, controlled, multicenter, international trial, 7376 patients with ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

FDA approved bronchodilator carmoterol and d-methamphetamine found in 23 drug tests from horses running at Lone Star Park ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...

In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...

Independent investment company Breakthrough Victoria is investing $800,000 in Diag-Nose.io Medical (DNM), a Melbourne based ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD ... mainly with either long-acting muscarinic antagonist (LAMA) or long-acting ...

and a long-acting muscarinic antagonist (LAMA) in a single delivery device, in an extra-fine formulation. The drug is likely to be the first COPD triple therapy on the market, after Europe’s ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Diag-Nose.io hopes to transform management of chronic respiratory diseases globally using its AI-powered biomarker diagnostic ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...